Survey Results

Page: Demographic data

1. Your pseudonym (unique identifier)
	answered question	1,866
	skipped question	4
		Response Count
[ShowReplies]		1,866

2. Patient identifier (must be unique)
	answered question	1,866
	skipped question	4
		Response Count
[ShowReplies]		1,866

Page: Diagnosis

3. Was this patient diagnosed with multiple myeloma?
	answered question		1,836
	skipped question		34
		Response Percent	Response Count
Yes		99.8%	1,833
No		0.2%	3

Page: Diagnostic Testing

4. Did this patient's baseline diagnostic evaluation include serum beta₂-microglobulin level for staging or assessment of prognosis? (Measure 1)
	answered question		1,800
	skipped question		70
		Response Percent	Response Count
Yes		87.1%	1,567
No		12.7%	229
Other (please specify) [ShowReplies]		0.4%	8

5. Did this patient's baseline diagnostic evaluation include serum albumin level for staging purposes? (Measure 2)
	answered question		1,800
	skipped question		70
		Response Percent	Response Count
Yes		97.3%	1,752
No		2.2%	40
Other (please specify) [ShowReplies]		0.4%	8

6. Did you use published staging system to help plan your patient's treatment? (Measure 3)
	answered question		1,800
	skipped question		70
		Response Percent	Response Count
Yes		81.2%	1,462
No		18.9%	340

Page: Published staging system

7. Which published staging system did you use?
	answered question		1,464
	skipped question		406
		Response Percent	Response Count
Durie/Salmon		51.3%	751
International Staging System		47.3%	692
Other (please specify) [ShowReplies]		1.5%	22

Page: Smoldering/Stage I Myeloma

8. Does this patient have smoldering or Stage I myeloma?
	answered question		1,794
	skipped question		76
		Response Percent	Response Count
Yes		14.8%	265
No		85.7%	1,537

Page: Smoldering or Stage I Myeloma Evaluation

9. Have you evaluated this patient for progression within the past 6 months? (Measure 4)
	answered question		283
	skipped question		1,587
		Response Percent	Response Count
Yes		92.9%	263
No		4.2%	12
Other (please specify) [ShowReplies]		2.8%	8

Page: Evaluated within 6 months

10. Which of the following were included in your evaluation?
	answered question		258
	skipped question		1,612
		Response Percent	Response Count
CBC		96.9%	250
Calcium		95.0%	245
Creatinine		97.3%	251
Serum protein electrophoresis		85.3%	220
Quantitative immunoglobulins		84.5%	218
Serum free light chains		58.1%	150
24-hr urine protein electrophoresis		45.7%	118
Other (please specify) [ShowReplies]		15.5%	40

Page: Bone Survey

11. Has this patient had a radiographic bone survey, including long bones, within the past 12 months? (Measure 5)
	answered question		1,786
	skipped question		84
		Response Percent	Response Count
Yes		83.0%	1,482
No		15.5%	276
Other (please specify) [ShowReplies]		1.9%	34

Page: Bone Disease

12. Did this multiple myeloma patient have documented bone disease (lytic lesions or osteopenia)?
	answered question		1,784
	skipped question		86
		Response Percent	Response Count
Yes		74.9%	1,337
No		25.4%	453

Page: Documented Bone Disease

13. Has this patient ever been treated with bisphosphonates? (Measure 6)
	answered question		1,772
	skipped question		98
		Response Percent	Response Count
Yes		75.6%	1,339
No		24.8%	439

Page: Bisphosphonates

14. Were you monitoring renal function in this patient by measuring serum creatinine prior to the most recent bisphosphonate administration? (Measure 7)
	answered question		1,354
	skipped question		516
		Response Percent	Response Count
Yes		98.4%	1,332
No		0.9%	12
Other (please specify) [ShowReplies]		0.7%	10

15. Did you document discussion about the risk of osteonecrosis of the jaw with this patient? (Measure 8)
	answered question		1,354
	skipped question		516
		Response Percent	Response Count
Yes		62.4%	845
No		35.1%	475
Other (please specify) [ShowReplies]		2.8%	38

Page: Immunization and clinical trials

16. Did this multiple myeloma patient receive an influenza vaccine in the last 12 months? (Measure 9)
	answered question		1,760
	skipped question		110
		Response Percent	Response Count
Yes		68.4%	1,204
No		23.2%	408
Other (please specify) [ShowReplies]		8.5%	150

17. Did this multiple myeloma patient receive an pneumococcal vaccine in the last 5 years? (Measure 10)
	answered question		1,758
	skipped question		112
		Response Percent	Response Count
Yes		56.1%	987
No		32.6%	573
Other (please specify) [ShowReplies]		11.5%	203

18. Has this patient been checked for clinical trial eligibility in the past year? (Measure 11)
	answered question		1,760
	skipped question		110
		Response Percent	Response Count
Yes		54.4%	957
No		41.8%	735
Other (please specify) [ShowReplies]		4.4%	77